Evista and Lidocaine and Epinephrine

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.

Raloxifene is more than 95% protein bound. Caution should be exercised if raloxifene is coadministered with other highly protein-bound drugs. The mechanism is displacement of the drug from its protein-binding site by raloxifene. Displacement may lead to increased free plasma concentrations and potentiate toxicity of drugs affected by raloxifene. Formal in-vitro studies indicate that raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen. The clinician may want to use caution when raloxifene is used with other highly-protein bound drugs, such as diazepam, diazoxide, or lidocaine.

Evista

Generic Name: raloxifene

Brand name: Evista

Synonyms: n.a.

What is Evista?

Lidocaine and Epinephrine

Generic Name: epinephrine / lidocaine

Brand name: D-Care 100X, Lignospan Forte, Lignospan Standard, Xylocaine MPF With Epinephrine, Xylocaine With Epinephrine

Synonyms: n.a.

What is Lidocaine and Epinephrine?